Logo image of BIO.DE

BIOTEST AG (BIO.DE) Stock Fundamental Analysis

FRA:BIO - Deutsche Boerse Ag - DE0005227201 - Common Stock - Currency: EUR

42.2  -0.4 (-0.94%)

Fundamental Rating

4

Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 72 industry peers in the Biotechnology industry. Both the profitability and the financial health of BIO get a neutral evaluation. Nothing too spectacular is happening here. BIO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

BIO had negative earnings in the past year.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BIO reported negative operating cash flow in multiple years.
BIO.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

BIO's Return On Assets of -1.73% is fine compared to the rest of the industry. BIO outperforms 66.67% of its industry peers.
BIO's Return On Equity of -4.81% is fine compared to the rest of the industry. BIO outperforms 68.06% of its industry peers.
The Return On Invested Capital of BIO (0.54%) is better than 75.00% of its industry peers.
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROIC 0.54%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
BIO.DE Yearly ROA, ROE, ROICBIO.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

BIO's Operating Margin of 1.87% is fine compared to the rest of the industry. BIO outperforms 75.00% of its industry peers.
BIO's Operating Margin has improved in the last couple of years.
BIO's Gross Margin of 23.19% is in line compared to the rest of the industry. BIO outperforms 51.39% of its industry peers.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 23.19%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
BIO.DE Yearly Profit, Operating, Gross MarginsBIO.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

5

2. Health

2.1 Basic Checks

BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO has about the same amount of shares outstanding.
BIO has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for BIO has been reduced compared to a year ago.
BIO.DE Yearly Shares OutstandingBIO.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIO.DE Yearly Total Debt VS Total AssetsBIO.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 2.36 indicates that BIO is not a great score, but indicates only limited risk for bankruptcy at the moment.
BIO's Altman-Z score of 2.36 is fine compared to the rest of the industry. BIO outperforms 70.83% of its industry peers.
The Debt to FCF ratio of BIO is 46.44, which is on the high side as it means it would take BIO, 46.44 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 46.44, BIO is in the better half of the industry, outperforming 76.39% of the companies in the same industry.
BIO has a Debt/Equity ratio of 1.26. This is a high value indicating a heavy dependency on external financing.
BIO's Debt to Equity ratio of 1.26 is in line compared to the rest of the industry. BIO outperforms 40.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Altman-Z 2.36
ROIC/WACC0.09
WACC6.01%
BIO.DE Yearly LT Debt VS Equity VS FCFBIO.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BIO has a Current Ratio of 4.93. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BIO (4.93) is better than 81.94% of its industry peers.
BIO has a Quick Ratio of 1.66. This is a normal value and indicates that BIO is financially healthy and should not expect problems in meeting its short term obligations.
BIO has a Quick ratio (1.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 1.66
BIO.DE Yearly Current Assets VS Current LiabilitesBIO.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

BIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.24%.
BIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.85%.
BIO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIO.DE Yearly Revenue VS EstimatesBIO.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO.DE Yearly EPS VS EstimatesBIO.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

BIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 27.85, which means the current valuation is very expensive for BIO.
Based on the Price/Forward Earnings ratio, BIO is valued cheaply inside the industry as 80.56% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 37.11. BIO is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 27.85
BIO.DE Price Earnings VS Forward Price EarningsBIO.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BIO is valued a bit cheaper than the industry average as 72.22% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 115.96
EV/EBITDA 43.06
BIO.DE Per share dataBIO.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

BIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

BIO has a yearly dividend return of 0.09%, which is pretty low.
Compared to an average industry Dividend Yield of 9.63, BIO pays a better dividend. On top of this BIO pays more dividend than 90.28% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, BIO's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.09%

5.2 History

On average, the dividend of BIO grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
BIO.DE Yearly Dividends per shareBIO.DE Yearly Dividends per shareYearly Dividends per share 2019 0 0 0 0 0

5.3 Sustainability

The dividend of BIO is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BIO.DE Yearly Income VS Free CF VS DividendBIO.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

More info and screens

BIOTEST AG

FRA:BIO (6/6/2025, 7:00:00 PM)

42.2

-0.4 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-04 2025-08-04
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.67B
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.09%
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.85
P/S 2.63
P/FCF 115.96
P/OCF 115.96
P/B 3.28
P/tB 3.39
EV/EBITDA 43.06
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY3.59%
FCF(TTM)0.36
FCFY0.86%
OCF(TTM)0.36
OCFY0.86%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROCE 0.95%
ROIC 0.54%
ROICexc 0.56%
ROICexgc 0.57%
OM 1.87%
PM (TTM) N/A
GM 23.19%
FCFM 2.27%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Debt/EBITDA 12.19
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.82
Cash Conversion 27.43%
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 1.66
Altman-Z 2.36
F-Score3
WACC6.01%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A